Proposición de consenso para el uso de yodo 131 en el tratamiento de la tirotoxicosis y el cáncer del tiroides

• Patricio Michaud Ch. ^[1]
  1. [1] Sociedad Chilena de Endocrinología y Metabolismo
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 126, Nº. 7, 1998, págs. 855-865
• Idioma: español
• Enlaces
  • Texto completo
• Resumen

  • Consensus porposal on the use of iodine-131 in hyperthyroidism and thyroid cancer A consensus meeting held by the Chilean Endocrinological Society reached to 22 consensus proposals on the use of iodine-131 in hyperthyroidism and thyroid cancer, that are reported in this paper. Some of these propositions are: 1) Hyperthyroidism: A previous 131I uptake test must be performed. A calculated or an ablative dose should be administered. Hypothyroidism must be considered an objective rather than a complication. In patients with cardiovascular risk, normal thyroid function must be attained with propythioturacil. In cases of treatment failure, the dose should not be repeated before six months. It must be used with used with caution in children and teenagers. 2) Thyroid cancer: A iodine free diet is recommended prior to the therapeutic dose. A 100 mCi complementary ablative dose should be given after surgery, with a posterior exploration. This examination must not be done routinely, and if required, a 5 mCi dose should be used. For the treatment of metastases, a dose of 150 to 200 mCi is recommended. There is no radiation risk in hyperthyroidism or thyroid cancer. The only absolute contraindication is pregnancy. Recommendations for radiological protection are formulated. Hospitalization is suggested to protect other people from radiation exposure.